Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,660 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Resilient together-ALS: leveraging the NDD transdiagnostic framework to develop an early dyadic intervention for people with amyotrophic lateral sclerosis and their informal care-partners.
Rush CL, Lester EG, Manglani H, Woodworth E, Vitolo O, Fava M, Berry JD, Brizzi K, Babu S, Lindenberger EC, Curtis JR, Vranceanu AM. Rush CL, et al. Among authors: babu s. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Jun 22:1-8. doi: 10.1080/21678421.2023.2224400. Online ahead of print. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 37345437 Review.
Class I and II histone deacetylase expression is not altered in human amyotrophic lateral sclerosis: Neuropathological and positron emission tomography molecular neuroimaging evidence.
Dios AM, Babu S, Granucci EJ, Mueller KA, Mills AN, Alshikho MJ, Zürcher NR, Cernasov P, Gilbert TM, Glass JD, Berry JD, Atassi N, Hooker JM, Sadri-Vakili G. Dios AM, et al. Among authors: babu s. Muscle Nerve. 2019 Oct;60(4):443-452. doi: 10.1002/mus.26620. Epub 2019 Jul 16. Muscle Nerve. 2019. PMID: 31241177
Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis.
Babu S, Macklin EA, Jackson KE, Simpson E, Mahoney K, Yu H, Walker J, Simmons Z, David WS, Barkhaus PE, Simionescu L, Dimachkie MM, Pestronk A, Salameh JS, Weiss MD, Brooks BR, Schoenfeld D, Shefner J, Aggarwal S, Cudkowicz ME, Atassi N. Babu S, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Feb;21(1-2):15-23. doi: 10.1080/21678421.2019.1672750. Epub 2019 Oct 14. Amyotroph Lateral Scler Frontotemporal Degener. 2020. PMID: 31608711 Clinical Trial.
Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.
Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson T, Jackson CE, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha S, Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass JD, Johnson KM, Swenson A, Goyal NA, Pattee GL, Andres PL, Babu S, Chase M, Dagostino D, Dickson SP, Ellison N, Hall M, Hendrix K, Kittle G, McGovern M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, Tustison E, Vigneswaran P, Walker J, Yu H, Chan J, Wittes J, Cohen J, Klee J, Leslie K, Tanzi RE, Gilbert W, Yeramian PD, Schoenfeld D, Cudkowicz ME. Paganoni S, et al. Among authors: babu s. N Engl J Med. 2020 Sep 3;383(10):919-930. doi: 10.1056/NEJMoa1916945. N Engl J Med. 2020. PMID: 32877582 Free PMC article. Clinical Trial.
Measuring disease progression in primary lateral sclerosis.
Gilmore M, Elman L, Babu S, Andres P, Floeter MK. Gilmore M, et al. Among authors: babu s. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Nov;21(sup1):59-66. doi: 10.1080/21678421.2020.1837179. Amyotroph Lateral Scler Frontotemporal Degener. 2020. PMID: 33602016 Free PMC article.
Patient reported outcomes in ALS: characteristics of the self-entry ALS Functional Rating Scale-revised and the Activities-specific Balance Confidence Scale.
Chew S, Burke KM, Collins E, Church R, Paganoni S, Nicholson K, Babu S, Scalia JB, De Marchi F, Ellrodt AL, Moura LMVR, Chan J, Berry JD. Chew S, et al. Among authors: babu s. Amyotroph Lateral Scler Frontotemporal Degener. 2021 Nov;22(7-8):467-477. doi: 10.1080/21678421.2021.1900259. Epub 2021 Mar 26. Amyotroph Lateral Scler Frontotemporal Degener. 2021. PMID: 33771057
Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial.
Babu S, Hightower BG, Chan J, Zürcher NR, Kivisäkk P, Tseng CJ, Sanders DL, Robichaud A, Banno H, Evora A, Ashokkumar A, Pothier L, Paganoni S, Chew S, Dojillo J, Matsuda K, Gudesblatt M, Berry JD, Cudkowicz ME, Hooker JM, Atassi N. Babu S, et al. Neuroimage Clin. 2021;30:102672. doi: 10.1016/j.nicl.2021.102672. Epub 2021 Apr 15. Neuroimage Clin. 2021. PMID: 34016561 Free PMC article.
Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development.
Paganoni S, Berry JD, Quintana M, Macklin E, Saville BR, Detry MA, Chase M, Sherman AV, Yu H, Drake K, Andrews J, Shefner J, Chibnik LB, Vestrucci M, Cudkowicz ME; Healey ALS Platform Trial Study Group. Paganoni S, et al. Ann Neurol. 2022 Feb;91(2):165-175. doi: 10.1002/ana.26285. Epub 2022 Jan 10. Ann Neurol. 2022. PMID: 34935174 Review.
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial.
Paganoni S, Hendrix S, Dickson SP, Knowlton N, Berry JD, Elliott MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson TD, Jackson C, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha SS, Miller TM, Scelsa SN, Vu TH, Fournier C, Johnson KM, Swenson A, Goyal N, Pattee GL, Babu S, Chase M, Dagostino D, Hall M, Kittle G, Eydinov M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, Tustison E, Vigneswaran P, Yu H, Cohen J, Klee J, Tanzi R, Gilbert W, Yeramian P, Cudkowicz M. Paganoni S, et al. Among authors: babu s. J Neurol Neurosurg Psychiatry. 2022 May 16;93(8):871-5. doi: 10.1136/jnnp-2022-329024. Online ahead of print. J Neurol Neurosurg Psychiatry. 2022. PMID: 35577511 Free PMC article.
1,660 results